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documentation of the searches is crucial to ensure the best possible acceptance of 
evidence in the AMNOG process.
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AnAlysis of PublisHed HeAltH tecHnology Assessments (HtA) in 
RussiA And its PlAce in RussiAn ReimbuRsement system
Kalbasko A., Heemstra L., Nijhuis T.
Quintiles, Hoofddorp, The Netherlands
Objectives: Currently there is no formal HTA agency in Russia, although the need 
for HTA as an evidence tool for policy makers is increasing due to budget constraints. 
However, there are HTA bodies which to some extent influence decison makers 
through publications of pharmacoeconomic studies. The objective of the present 
study was to gain insights into the current activities of existing HTA organizations 
and research trends in developing HTA in Russia. MethOds: A manual search of 
four Russian HTA organizations’ websites was conducted to find pharmacoeco-
nomic assessments published from 1998 onwards. Per agency, all relevant reports 
were categorized by therapeutic area and publication date. Any revealed patterns 
in the HTA topics were in-depth analyzed and compared with the World Health 
Organization (WHO) country profile of Russia. Results: In total, 180 pharmaco-
economic assessments published by four Russian HTA organizations were identi-
fied. Overall, the majority of studies were performed in cardiovascular (n= 45; 25%) 
and oncology (n= 32; 18%) disease areas, which are according to the WHO, the two 
leading causes of death, both in Russia and globally. The total number of pharma-
coeconomic publications per year has been constantly increasing from one study in 
1998 to 26 in 2009, however with fewer reports published in 2010-2013 (32 HTAs in 
three years). When reported, the potential willingness-to-pay (WTP) threshold for 
cost-effectiveness was suggested to be 3*Gross Domestic Product (GDP) per capita 
as recommended by WHO, which equals to approximately 30,000 euro per Quality 
Adjusted Life Year (QALY) gained. cOnclusiOns: Although formally Russia does 
not have a transparent HTA based reimbursement process, existing HTA organiza-
tions are constantly developing and gaining HTA experience by conducting assess-
ments in the therapeutic areas with the highest burden on Russian population. 
These areas of interest, as well as an approach to define WTP threshold, match with 
WHO data and recommendations.
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systemAtic liteRAtuRe Reviews At tHe HeARt of HeAltH tecHnology 
Assessment: A comPARison AcRoss mARkets
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Solutions, Ann Arbor, MI, USA
Objectives: Requirements for systematic literature reviews (SLRs) within a 
Health Technology Assessment (HTA) submission vary across the world. The objec-
tive of this study is to compare clinical and economic SLR requirements issued 
by eight HTA agencies in the UK (England and Wales, Wales, Scotland), Ireland, 
Germany, Sweden, Canada, and Australia. MethOds: SLR requirements issued by 
the National Institute for Health and Care Excellence (NICE), All Wales Medicines 
Strategy Group (AWMSG), Scottish Medicines Consortium (SMC), National Centre 
for Pharmacoeconomics (NCPE), Gemeinsamer Bundesausschuss (G-BA) (Federal 
Joint Committee), The Dental and Pharmaceutical Benefits Agency (TLV), Canadian 
Agency for Drugs and Technologies in Health (CADTH), and Pharmaceutical Benefits 
Advisory Committee (PBAC) were compared, and a checklist of requirements was 
compiled. Results: SLRs of the clinical and economic evidence underpin the HTA 
process. However, HTA agencies vary on the specific requirements for each and the 
need for critical appraisal of identified clinical studies and economic analyses. NICE 
requirements are the most prescriptive, whereas AWMSG and TLV have few stated 
SLR requirements. All agencies require a clinical SLR, although AWMSG does not 
specify outright but requires a clinical SLR to determine economic model inputs. 
Four agencies require both a clinical SLR and critical appraisal of the included stud-
ies (NICE, NCPE, G-BA, and PBAC), although recommended appraisal tools vary. NICE 
and CADTH require both an SLR and a critical appraisal of existing economic evalu-
ations for the intervention of interest; PBAC requires an SLR of only economic evalu-
ations. NICE, SMC, AWMSG, and NCPE require an SLR of utility data, and only NICE 
and SMC specify the need for an SLR of cost and resource use data. A more detailed 
analysis of specific methodology requirements will be presented. cOnclusiOns: 
Although SLR requirements vary between HTA agencies, a clinical SLR is a key 
requirement for all eight agencies investigated.
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Jebrail F.1, Duong M.2, Shum D.2
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Objectives: To assess the level of transparency of health technology assessment 
(HTA) organizations in eight countries (Australia, Canada, Brazil, France, Germany, 
Italy, Spain, and the UK). MethOds: Nine national review bodies carrying out HTAs 
for the purposes of reimbursement and funding decisions within their respective 
countries were assessed according to 33 transparency parameters. The parameters 
were designed to assess the level of transparency in the HTA processes, clinical and 
economic reviews, and stakeholder involvement. Using a modified Delphi process, 
each parameter was weighted based on its importance to transparency and given a 
score from one to ten. A review of each national body was conducted to determine 
whether or not they included each of the 33 parameters. Data from public sources 
(i.e., organization websites) were utilized and interviews with international experts 
were conducted to verify the information. Total scores were calculated and con-
verted to a transparency index, with 100% being the most transparent. The score was 
adjusted for review bodies that did not require economic evaluations for their HTA 
process. Results: The level of transparency varies greatly amongst the HTA organi-
Objectives: In Australia, the decision process for the reimbursement of orphan 
drugs on the Life-Saving Drugs Program (LSDP) is centred on a drug’s ability to 
meet strict criteria as specified and assessed by both the Pharmaceutical Benefits 
Advisory Committee (PBAC) and the LSDP Advisory Committees. The objective of this 
research was to investigate the key determinants of PBAC decisions with respect to 
the LSDP criteria in order to understand the key challenges facing new treatments 
seeking LSDP funding. MethOds: A systematic search was conducted of all avail-
able Public Summary Documents (PSDs) from July 2005 to April 2013, to identify 
products that have sought listing on the LSDP. The selected PSDs were reviewed 
and data extracted according to categories defined by the LSDP criteria. Data were 
then qualitatively analysed within and across categories to identify key themes 
and concepts influencing decisions. Quantitative analyses were also conducted on 
the number of submissions, rejections, deferrals and the time from when a product 
first sought reimbursement to when funding was initiated. Results: Since the 
LSDP was created in 1995 only 12 products have sought LSDP funding, 10 are cur-
rently reimbursed covering 7 disease areas. Of the applications reviewed, 58% of 
submissions were immediately referred from the PBAC to LSDP for funding, 17% 
were initially rejected and after subsequent submissions have been funded, and 
25% of applications are yet to receive funding. The average time from the first PBAC 
consideration of a product until funding on the LSDP is 19.7months. The most com-
mon reason for rejection was around uncertainty in a drug’s ability to significantly 
prolong life and the appropriateness of surrogate outcomes to accurately predict 
long-term survival. cOnclusiOns: This analysis shows there is a pathway to reim-
bursement of high cost orphan drugs when there is a reasonable level of evidence 
supporting survival gains.
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How does tHe unceRtAinty ARound tHe exPected iceR Affect nice 
decisions?
Barber R., Steeves S., Kusel J., Wilson T., Hamerslag L.
Costello Medical Consulting Ltd., Cambridge, UK
Objectives: In the UK, NICE assesses health technologies based on clinical 
and cost-effectiveness evidence. Recommendations ensure NHS patients have 
access to the most clinically effective treatments, whilst using NHS resources 
cost-effectively. Nevertheless, cost-effectiveness analyses are susceptible to limi-
tations which make the true value of a technology uncertain. This study investi-
gates what other factors NICE considers when making recommendations under 
uncertainty. MethOds: All Single Technology Appraisals (STAs) published by NICE 
between 2011-2013 inclusive were reviewed. Recommendations were identified 
as being made under uncertainty if there was a less than 50% probability that the 
intervention was cost-effective at a willingness-to-pay threshold of £20,000 per 
QALY gained. NICE committee reports for these appraisals were reviewed to deter-
mine the factors taken into account when making a recommendation. Results: 
Of 64 STAs published in the studied period, 31 interventions were identified with 
uncertainty at the willingness-to-pay threshold of £20,000, of which 18 (58%) were 
recommended by NICE. Moreover, only 4 (22%) recommended STAs with uncer-
tainty at £20,000 had a greater than 50% probability of being cost-effective at a 
threshold of £30,000. Of the STAs recommended under uncertainty, 13 (72%) had a 
patient access scheme (PAS) in place, while 3 (17%) fulfilled end-of-life treatment 
criteria. Health-related benefits not captured in the manufacturer’s economic 
model that were likely to lower the ICER, innovative technologies, or interven-
tions satisfying an unmet clinical need were also taken into account. For exam-
ple, fingolimod was recommended by NICE for treatment of multiple sclerosis 
based on its oral rather than intravenous formulation and because benefits from 
a reduced caregiving need were not accounted for in the manufacturer’s economic 
model. cOnclusiOns: Even under uncertainty, NICE often recommends new 
technologies, particularly if a PAS is in place or if additional costs are deemed to 
be justified by the benefit provided to patients or their families.
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dossieRs in tHe geRmAn Amnog PRocess
Witt B.1, Bakker K.2, Volmer T.1
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Objectives: The benefit assessment of new drugs in Germany requires the sub-
mission of a value dossier including systematic searches. The majority of dossiers 
are methodically inspected and assessed by the German Institute for Quality and 
Efficiency in Healthcare (IQWiG). The study’s objective was the analysis of com-
mon deficiencies in systematic searches and their consequences for the IQWiG 
assessment. MethOds: A total of 37 IQWiG assessment reports were analysed 
with regard to all comments made on the presented systematic searches in the 
dossier of the pharmaceutical company. A distinction was made between literature 
and study searches. The respective IQWiG comments were categorized and listed. 
Inadequate searches were examined in terms of consequences for the assessment 
by the IQWiG. Consequences were divided into those affecting the search required 
for the substance itself and those carried out for indirect comparisons/ further 
investigations. Results: A total of 4 of the 37 dossiers passed the IQWiG assess-
ment without deficiencies. Out of all analysed searches a total of 104 deficiencies 
were found, of which the most frequent ones referred to the search strings (32%) and 
the documentation of the search (25%). In the consistency check on the number of 
hits deviations were found by the IQWiG in 13%; 92% of the inconsistencies occurred 
in study-registry versus 8% in literature searches. There were no consequences in 
62% (23/37) for the substance-search and in 22% (8/37) for indirect comparisons/ 
further investigations. Non-consideration of study results, which was the most 
frequent consequence of an inadequate search, occurred in 24% for the substance-
search and in 32% for indirect comparisons/further analyses. cOnclusiOns: The 
methodological requirements for systematic searches to be accepted by the IQWiG 
are not achieved in the majority of dossiers. An adequate design and a careful 
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workbook. Results: Of the 71 STAs published, ACDs were produced for 60 technolo-
gies, while 11 (15%) proceeded straight to FAD. All submissions which proceeded 
directly to FAD were recommended (full or optimised) in the final guidance. Twelve 
STAs (20%) received a “minded no” at ACD; however, 11 of these (92%) were reversed 
within the FAD on the basis of additional data provided by the manufacturers in 
the form of economic analyses (n= 5) or patient access schemes (PAS) (n= 6). Of the 
35 “not recommended” at ACD, 15 (43%) were ultimately recommended within the 
FAD through the introduction or revision of a PAS and/or submission of additional 
analyses. cOnclusiOns: If manufacturers can demonstrate a robust clinical and 
economic argument in their initial submission the chances of a FAD being produced 
without the requirement of an ACD are greatly increased. Furthermore, ACD deci-
sions can also be overturned; technologies which receive a “minded no” or “not 
recommended” at ACD stage can achieve a recommendation at FAD by presenting 
additional analyses or introducing/modifying a PAS.
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comPARison of dRug Assessments in fRAnce, geRmAny And tHe united 
kingdom: is euRoPeAn HtA A ReAlity?
Troubat A., Perrin L.
IMS Health, PARIS LA DEFENSE, France
Objectives: In 2006, the EUnetHTA project was launched. One of its main strategic 
objectives was to strengthen the link between HTA and health care policy making 
in the EU. Seven years after EUnetHTA establishment, the objective of this study 
was to compare HTA agencies’ assessments in France, Germany and UK, focusing 
on method and outcomes. MethOds: Scope of the study was all the products 
getting a positive opinion from CHMP during two years, starting at January 1, 2011. 
Comparison between assessments was made for products assessed by the three 
HTA agencies: IQWiG, NICE, and HAS. Results: A total of 87 drugs were included in 
this study. 11 (13%) have been assessed by the three agencies. Among these drugs, 
more than 50% (6) were cancer treatment. HAS was the first to assess drug in 6 cases 
(mean delay between CHMP positive opinion and assessment: 223 days), followed 
closely by IQWiG (242 days), then by NICE (354 days). IQWiG segmented the patient 
population defined by the manufacturer into different sub-populations in 6 assess-
ments, HAS in 2, NICE never. NICE was the only agency who did not recommend a 
drug for cost-effectiveness reasons (2 assessments). In three assessments, IQWiG 
concluded that there was no benefit proven for the whole population; regarding 
the same drugs, HAS concluded there was minor improvement in actual benefit 
twice. cOnclusiOns: Some major trends emerge in the assessments studied: use 
of indirect comparisons, added therapeutic value weighted by severity and fre-
quency of side effects and uncertainty. Nevertheless, comparator choices, perception 
of clinical benefits and risks, budget impact and overall method still differ between 
the three HTA agencies studied, leading to different outcomes for drugs assessed.
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Objectives: To examine whether the Delphi method can provide a convenient 
tool for selecting medical technologies for inclusion in the National List of Health 
Services (NLHS) in Israel under a pre-defined budget constraint. MethOds: The 
Delphi method was applied in two groups: medical specialists (oncologists and 
cardiologists) and observers in the NLHS committee. Participants in each group 
were anonymously asked to choose five of ten suggested technologies from the list 
of technologies submitted for inclusion in the 2012 NLHS and rank them accord-
ing to importance. Subsequently, the participants repeated the experiment after 
receiving aggregated feedback on the relative ranking of each technology within the 
same group after the first round. Comparison of the results was performed using 
descriptive statistics and non-parametric tests. Results: After two rounds of the 
experiment, observers and medical specialists reached agreement on four of the 
five highest ranked technologies in each field (oncology and cardiology) regarding 
their importance to be included in the NLHS. Three of these four technologies were 
indeed included in the NLHS for 2012. cOnclusiOns: The Delphi method is one of 
the best-known techniques to control group interaction and reach a consensus by 
utilizing the expertise of committee members. The study demonstrated the feasibil-
ity using the Delphi method for ranking health care technologies.
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wHicH sHould be tHe coRRect nmA to be used? A Review of HtA 
RecommendAtions
Solozabal M.1, Roset M.1, Rojas-Farreras S.1, González-Rojas N.2, Gil A.2
1IMS Health, Barcelona, Spain, 2Boehringer Ingelheim, Sant Cugat del Vallès (Barcelona), Spain
Objectives: In the lack of head-to-head comparative trials to demonstrate the effi-
cacy of new treatments, it is common to use network meta-analysis (NMA), includ-
ing indirect treatment comparison (ITC) or combine direct and indirect evidence 
through mixed treatment comparison (MTC). Due to the increasing number of drugs 
approved for the same indication and the increasing complexity of networks for 
treatments comparisons, new methods of MTC taking into account all the com-
parisons have aroused. Health Technology Assessment (HTA) bodies increasingly 
demand NMA although different recommendations about the methodologies to be 
applied exist. This study aims to review recommendations regarding ITCs and MTCs 
among the main HTA bodies. MethOds: A review of methodologies for drug com-
parison recommended by the main HTA bodies was performed. Recommendations 
related to evidence identification methods, assessment of homogeneity of studies 
and populations to be combined and statistical approach for the analysis were also 
reviewed. Results: A systematic literature search is a prerequisite for most HTA bod-
zations studied. The transparency index scores were as follows: Institut für Qualität 
und Wirtschaftlichkeit im Gesundheitswesen/Gemeinsamen Bundesausschusses 
(Germany), National Institute for Health and Care Excellence (UK), pan-Canadian 
Oncology Drug Review (Canada), Common Drug Review (Canada), Pharmaceutical 
Benefits Advisory Committee (Australia), Comissão Nacional de Incorporação 
de Tecnologias (Brazil), Haute Autorité de Santé (France), Agencia de Evaluación 
de Tecnologias Sanitarias (Spain), and Agenzia Italiana del Farmaco (Italy) were 
97%, 96%, 91%, 83%, 78%, 70%, 67%, 53%, and 25%, respectively. cOnclusiOns: 
Transparency amongst HTA organizations is progressively becoming the interna-
tional standard. However, the extent of transparent processes and procedures proves 
to be heterogeneous amongst international review organizations.
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exPloRing tHe key decision dRiveRs PRovided by HtA Agencies 
Rejecting submissions witH iceRs loweR tHAn tHe tHResHold
Walsh S.C.M., Goodrich K.
HERON Evidence Development Ltd., London, UK
Objectives: Health technology assessment (HTA) agencies use an incremental 
cost-effectiveness ratio (ICER) threshold generally understood to be £30,000 for NICE 
(England), £20,000 for the SMC (Scotland), CAN$50,000 for CADTH (Canada), and 
AUS$42,000 for PBAC (Australia). To help inform future submissions, we assessed 
the rationale provided by the four HTA agencies when submissions were rejected 
despite the reported ICERs being lower than these thresholds. MethOds: All HTA 
appraisals from January 2000 to May 2013 from NICE, SMC, CADTH, and PBAC were 
included in the analysis. Multiple technology appraisals, resubmissions, vaccination 
programmes, requests for advice, and submissions for which an ICER could not be 
determined were excluded from the analysis. The full responses of the remaining 
appraisals were reviewed, with the submitted ICER, recommendation, and reason-
ing behind the recommendation extracted. Results: A total of 594 submissions 
met the inclusion criteria. 354 submissions across the four HTA bodies included a 
lower-than-threshold ICER, with 107 (30.2%) of these submissions rejected. Across 
the agencies, the most common reasons for rejection were use of an inappropriate 
patient population or comparator (45/107), uncertainty regarding the clinical ben-
efits (32/107), and use of economic evidence that was not sufficiently robust (40/107). 
The reasons for rejection were consistent across the four agencies, with a similar 
proportion basing their decision at least partly on one of the three reasons provided 
above: NICE (92.9%), SMC (92.0%), CADTH (93.3%), PBAC (93.8%). cOnclusiOns: A 
large proportion of submissions were rejected despite ICERs below the threshold. 
In instances where decisions went against the ICER thresholds, there was a clear 
tendency for identifiable problems with the clinical and economic assumptions to 
diminish the reliability of the ICERs presented. This result highlights that a lower-
than-threshold ICER is not enough for a positive recommendation and manufac-
turers must support their submission with accurate and reliable data to achieve a 
favourable outcome.
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itAly comPARes to fRAnce, geRmAny And tHe united stAtes
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Objectives: A new drugs’ innovation benefit is commonly evaluated, both in 
Europe and the USA. Most of the new pharmaceutical launches have to be evalu-
ated on the level of innovation that they offer as part of the market access process. 
The objective of this abstract is to give an example of the variability that emerges 
in the innovation scores given by the Italian agency, AIFA, as compared to those of 
France, Germany and the USA. MethOds: Drugs listed on the AIFA website as show-
ing potential or important innovation, were used as a benchmark to measure how 
innovation benefit assessments performed in France, Germany and the USA deviate. 
The innovation benefit was measured through: the ASMR score (Amélioration du 
Service Médical Rendu) in France, as published on the HAS website (Haute Autorite’ 
de Sante’); the level of additional benefit in Germany, as published on the G-BA 
website (Gemeinsame Bundesausschuss); the type of approval procedure as pub-
lished on the FDA (Food and Drug administration) website. In the case of the USA, 
standard approval vs. priority review was used as a proxy measure of the level of 
innovation. Results: The results of the innovation benefit’s evaluations performed 
in France, Germany and the USA differ from those performed by AIFA in 74%, 33% 
and 58% of cases respectively. The lower percentage in Germany is due to lim-
ited available information compared to other markets. cOnclusiOns: The level 
of variability that exists between the outcomes of the innovativeness evaluation 
performed in different countries suggests that although the definition of innova-
tion may appear straightforward, it is open to different interpretations by different 
health care systems.
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nice stA decisions: An AnAlysis of How Advice diffeRs between 
PReliminARy And finAl guidAnce
Murray G., McLeod C., Howells R.
Abacus International, Manchester, UK
Objectives: The National Institute for Health and Care Excellence (NICE) estab-
lished the Single Technology Appraisal (STA) programme to evaluate the clinical 
and cost-effectiveness of medical technologies and provide mandatory guidance 
on how they should be used within the National Health Service (NHS) in the UK. The 
objective of this analysis is to explore how NICE advice differs between preliminary 
and final guidance in the STA process and identify actions manufacturers could 
take to increase their chances of a successful submission. MethOds: For STAs 
published between February 2010 and May 2013, the appraisal consultation docu-
ment (ACD) and final appraisal determination (FAD) were identified. The guidance 
issued in these documents was compared and contrasted, and the key clinical and 
economic evidence that affected recommendations were extracted into an Excel 
